Table 1. Demographic and clinical data of leprosy patients with ENL (n = 4 patients from UK not shown as a subgroup).
| Centre | ALL (n = 292) | BRAZIL (n = 47) | ETHIOPIA (n = 51) | INDIA—BLP (n = 62) | INDIA—TLM (n = 60) | NEPAL (n = 47) | PHILIPPINES (n = 21) | |
|---|---|---|---|---|---|---|---|---|
| Male: Female | 2.8:1 (215:77) | 3.7:1 | 1.1:1 | 3.8:1 | 5:1 | 3.3:1 | 20:1 | |
| Median Age (years, [Range]): | 32 [12–73] | 37 [19–73] | 24 [12–55] | 32 [14–68] | 30 [12–65] | 30 [18–60] | 28 [21–50] | |
| Leprosy type: n (%) | Borderline borderline (BB) leprosy | 5 (1.7) | 0 (0) | 3 (5.9) | 1 (1.6) | 1 (1.7) | 0 (0) | 0 (0) |
| BL leprosy | 65 (22.3) | 7 (14.9) | 7 (13.7) | 24 (38.7) | 23 (38.3) | 3 (6.4) | 0 (0) | |
| LL | 222 (76.0) | 40 (85.1) | 41(80.4) | 37 (59.7) | 36 (60.0) | 44 (93.6) | 21 (100) | |
| Median Mean Bacterial Index (BI) at leprosy diagnosis (288 BI available) | 4 [0–6] | 4.5 [1.25–6] | 3.5 [0–6] | 4 [0.4–6] | 4 [2–6] | 4 [1–5.25] | 5 [4.33–5] | |
| Reaction status at leprosy diagnosis: n (%) | None | 113 (38.7) | 32 (68.1) | 22 (43.1) | 12 (19.4) | 12 (20.0) | 20 (42.6) | 13 (61.9) |
| Type 1 | 13 (4.5) | 0 (0) | 3 (5.9) | 0 (0) | 0 (0) | 6 (12.8) | 3 (14.2) | |
| ENL | 143 (49.0) | 13 (27.7) | 26 (51.0) | 49 (79.0) | 35 (58.3) | 19 (40.4) | 1 (4.8) | |
| Neuritis | 23 (7.9) | 2(4.3) | 0 (0) | 1 (1.6) | 13 (21.7) | 2 (4.3) | 4 (19.0) | |
| MDT status: (n = 291) n (%) | No previous MDT | 17 (5.8) | 2 (4.3) | 10 (19.6) | 4 (6.5) | 1 (1.7) | 0 (0) | 0 (0) |
| Current | 101 (34.6) | 11 (23.4) | 8 (15.7) | 12 (15.4) | 37 (61.7) | 31 (66.0) | 2 (9.5) | |
| Completed | 173 (59.2) | 34 (72.3) | 33 (64.7) | 45 (72.6) | 22 (36.7) | 16 (34.0) | 19 (90.5) | |
| HIV status: n (%) | Negative | 121 (41.4) | 22 (46.8) | 49 (96.1) | --- | --- | 47 (100) | —— |
| Positive | 1 (0.003) | --- | 1 (2.0) | --- | --- | 0 (0) | —— | |
| Not known | 170 (58.2) | 25 (53.2) | 1 (2.0) | 62 (100) | 60 (100) | 0 (0) | 21 (100) | |
| ENL type: n (%) | Acute | 100 (34.2) | 17 (36.2) | 21 (41.2) | 21 (33.9) | 24 (40.0) | 9 (19.1) | 8 (38.1) |
| Recurrent | 95 (32.5) | 12 (25.5) | 11 (21.6) | 24 (38.7) | 30 (50.0) | 16 (34.0) | 1 (4.8) | |
| Chronic | 97 (33.2) | 18 (38.3) | 19 (37.3) | 17 (27.4) | 6 (10.0) | 22 (46.8) | 12 (57.1) | |
| Physician determined ENL severity (n = 289): n (%) | Mild | 53 (18.3) | 10 (21.3) | 3 (5.9) | 21 (33.9) | 2 (3.3) | 16 (34.0) | 1 (4.8) |
| Moderate | 114 (39.4) | 14 (29.8) | 16 (31.4) | 31 (50.0) | 49 (81.7) | 2 (4.3) | 0 (0) | |
| Severe | 122 (42.2) | 23 (48.9) | 30 (58.8) | 10 (16.1) | 9 (15.0) | 29 (61.7) | 20 (95.2) | |